newsfilter
← Latest News
GlobeNewswire·

InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan

Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses evaluatedFindings